U.S. National Library of MedicineNational Institutes of Health
Skip navigation
MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You
  FAQs Site Map About MedelinePlus Contact Us
español
Reuters Health Information Logo

Vitamin K may boost effects of cancer pill Nexavar

Printer-friendly version E-mail this page to a friend

Reuters Health

Wednesday, April 22, 2009

Nexavar tablets are seen in this undated handout photo. REUTERS/Newscom/HandoutCHICAGO (Reuters) - Vitamin K may enhance the effects of the cancer drug Nexavar, which may allow patients to take lower, less-toxic doses, U.S. researchers said on Wednesday.

They said combining vitamin K with the cancer pill Nexavar or sorafenib sold by Onyx Pharmaceuticals Inc and German drugmaker Bayer AG helped it kill liver and pancreatic cancer in human cell cultures.

"K vitamins ... appear to enhance the effects of sorafenib, thus requiring lower, less-toxic doses," Dr. Brian Carr of Thomas Jefferson University in Philadelphia said in a statement.

"Many patients need to discontinue treatment with sorafenib because of the debilitating side effects," Carr said. "If we could lower the dose, more patients would be able to complete their treatment."

Nexavar is approved for use in liver kidney cancer and is being tested for an array of other cancers, including melanoma, lung and breast cancer. It had global sales last year of $678 million.

Carr said combining the drug with vitamin K may help patients avoid hand-foot syndrome, a common side-effect of Nexavar that affects about 20 percent of patients.

It typically causes painful sores on the soles of patients' feet that can prevent the patients from walking, said Carr, who presented his findings from two studies at the American Association for Cancer Research meeting in Denver.

He and colleagues tested both vitamin K1 and vitamin K in combination with sorafenib in pancreatic cell lines. Each combination inhibited cell growth, killed cells and slowed enzymes that promote cancer cell growth.

With vitamin K, the team could use half the normal dose and still slow cancer cell growth. Alone, the lower dose of sorafenib was ineffective.

In the second study, vitamin K1 also enhanced the effects of sorafenib in hepatocellular carcinoma or primary liver cancer.

Vitamin K is found in green, leafy vegetables such as kale, collard greens, broccoli, Brussels sprouts and parsley and is known to play a role in blood clotting and building bones.

(Editing by Maggie Fox and Bill Trott)


Reuters Health

© 2009 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies. For additional information on other Reuters media services please visit http://about.reuters.com/media/.

Related News:
More News on this Date

Related MedlinePlus Pages: